Hospira has successfully overturned two patents on Roche's top-selling breast cancer drug Herceptin in Britain, clearing the way for it to launch a cheaper copycat version in the country. Herceptin, an injectable antibody-based biotech drug, had worldwide sales of 6.08 billion Swiss francs ($6.90 billion) last year. U.S.-based Hospira has pioneered the development of so-called biosimilar versions of biotech drugs. Hospira recently launched the first antibody biosimilar in Europe, called Inflectra, which is a copy of Johnson & Johnson's and Merck & Co's Remicade drug for rheumatoid arthritis.
via Health News Headlines - Yahoo News http://ift.tt/1hl5tLB
No comments:
Post a Comment